These results indicate that recombinant podoplanin did not interfere with CLEC-2 quantification in our assay system, suggesting that epitope masking is unlikely to fully explain the observed reduction of plasma CLEC-2 levels in breast cancer patients. Here, PDPN is linked to breast cancer.